Bank of Nova Scotia’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.7M Sell
27,607
-7,754
-22% -$3.44M 0.02% 425
2026
Q1
$15.8M Sell
35,361
-62,559
-64% -$29.2M 0.03% 334
2025
Q4
$44.4M Buy
97,920
+11,668
+14% +$5.03M 0.07% 214
2025
Q3
$33.8M Buy
86,252
+36,643
+74% +$15.3M 0.06% 221
2025
Q2
$22.1M Buy
49,609
+21,921
+79% +$10.1M 0.05% 247
2025
Q1
$13.4M Sell
27,688
-19,409
-41% -$9.04M 0.03% 316
2024
Q4
$19M Sell
47,097
-27,573
-37% -$12.8M 0.03% 297
2024
Q3
$34.7M Buy
74,670
+23,303
+45% +$11.2M 0.07% 174
2024
Q2
$24.1M Sell
51,367
-174,569
-77% -$75.8M 0.05% 238
2024
Q1
$94.4M Buy
225,936
+163,589
+262% +$69.2M 0.19% 95
2023
Q4
$25.4M Buy
62,347
+3,384
+6% +$1.25M 0.05% 263
2023
Q3
$20.5M Buy
58,963
+33,942
+136% +$11.9M 0.05% 225
2023
Q2
$8.81M Buy
25,021
+1,670
+7% +$563K 0.02% 300
2023
Q1
$7.36M Sell
23,351
-19,317
-45% -$5.79M 0.02% 324
2022
Q4
$12.3M Buy
42,668
+8,942
+27% +$2.73M 0.03% 318
2022
Q3
$9.76M Sell
33,726
-31,302
-48% -$9.01M 0.03% 309
2022
Q2
$18.3M Buy
65,028
+21,550
+50% +$5.77M 0.04% 285
2022
Q1
$11.3M Sell
43,478
-57,781
-57% -$13.7M 0.02% 419
2021
Q4
$22.2M Sell
101,259
-387,200
-79% -$75.3M 0.03% 367
2021
Q3
$88.6M Buy
488,459
+447,537
+1,094% +$87.4M 0.16% 131
2021
Q2
$8.25M Sell
40,922
-9,642
-19% -$2.02M 0.02% 488
2021
Q1
$10.9M Sell
50,564
-69,477
-58% -$15.3M 0.02% 381
2020
Q4
$28.4M Buy
120,041
+26,344
+28% +$6.04M 0.06% 245
2020
Q3
$25.5M Sell
93,697
-322,893
-78% -$89.1M 0.07% 227
2020
Q2
$121M Buy
416,590
+53,626
+15% +$14.5M 0.42% 63
2020
Q1
$86.4M Buy
362,964
+302,317
+498% +$69.3M 0.3% 83
2019
Q4
$13.3M Buy
60,647
+3,585
+6% +$726K 0.03% 342
2019
Q3
$9.67M Buy
57,062
+8,974
+19% +$1.59M 0.03% 376
2019
Q2
$8.82M Sell
48,088
-649
-1% -$113K 0.04% 314
2019
Q1
$8.96M Sell
48,737
-20,015
-29% -$3.7M 0.04% 327
2018
Q4
$11.4M Buy
68,752
+16,808
+32% +$2.91M 0.05% 254
2018
Q3
$10M Buy
51,944
+23,977
+86% +$4.27M 0.04% 314
2018
Q2
$4.75M Sell
27,967
-4,347
-13% -$674K 0.03% 355
2018
Q1
$5.26M Sell
32,314
-7,395
-19% -$1.21M 0.03% 378
2017
Q4
$5.95M Sell
39,709
-4,051
-9% -$600K 0.03% 381
2017
Q3
$6.65M Sell
43,760
-72,499
-62% -$10.9M 0.04% 324
2017
Q2
$15M Buy
116,259
+59,397
+104% +$7.15M 0.08% 219
2017
Q1
$6.22M Buy
56,862
+51,357
+933% +$4.52M 0.03% 367
2016
Q4
$406K Buy
5,505
+490
+10% +$39.9K ﹤0.01% 644
2016
Q3
$437K Buy
5,015
+100
+2% +$9.45K ﹤0.01% 547
2016
Q2
$423K Buy
4,915
+320
+7% +$27.6K ﹤0.01% 527
2016
Q1
$365K Buy
4,595
+60
+1% +$5.43K ﹤0.01% 543
2015
Q4
$571K Buy
4,535
+10
+0.2% +$1.21K ﹤0.01% 480
2015
Q3
$471K Buy
4,525
+200
+5% +$25.7K ﹤0.01% 436
2015
Q2
$534K Buy
4,325
+128
+3% +$16.1K ﹤0.01% 352
2015
Q1
$495K Buy
4,197
+140
+3% +$16.8K ﹤0.01% 358
2014
Q4
$482K Hold
4,057
﹤0.01% 369
2014
Q3
$456K Buy
4,057
+293
+8% +$27.9K ﹤0.01% 374
2014
Q2
$356K Buy
3,764
+409
+12% +$28.7K ﹤0.01% 413
2014
Q1
$237K Buy
3,355
+108
+3% +$8.55K ﹤0.01% 512
2013
Q4
$241K Buy
3,247
+66
+2% +$4.6K ﹤0.01% 506
2013
Q3
$241K Buy
+3,181
New +$253K ﹤0.01% 460

Other funds holding VRTX

Bank of Nova Scotia's VRTX Position: Q2 2026 in Review

Bank of Nova Scotia reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q2 2026, selling an estimated $3.44M and leaving 27,607 shares worth $13.7M. The position accounts for 0.02% of the portfolio, ranked #425.

Bank of Nova Scotia first reported a position in VRTX in Q3 2013 and has held it in 52 quarters since. The position peaked at $121M in Q2 2020. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Bank of Nova Scotia held 27,607 shares of Vertex Pharmaceuticals worth $13.7M as of Q2 2026.
  • Bank of Nova Scotia sold 7,754 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.44M.
  • Vertex Pharmaceuticals made up 0.02% of Bank of Nova Scotia's portfolio in Q2 2026, its #425 holding.
  • Bank of Nova Scotia first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 52 quarters since.
  • Bank of Nova Scotia's Vertex Pharmaceuticals position peaked at $121M in Q2 2020.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.